• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20073 / 2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

25 April 2007/in 2007, AT7519 – CDK inhibitor, Products

2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-04-25 14:12:422016-11-25 14:13:062007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Supergen Sells Select Non-Core Assets to Intas Link to: Supergen Sells Select Non-Core Assets to Intas Supergen Sells Select Non-Core Assets to Intas Link to: SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 Link to: SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP4...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.